The pharmacology of nitroxyl (HNO) and its therapeutic potential: Not just the janus face of NO11This review is dedicated to the career of Prof. Herbert T. Nagasawa, a pioneer in the field of HNO chemistry, biochemistry and pharmacology.

Nazareno Paolocci, Matthew I. Jackson, Brenda E. Lopez, Katrina Miranda, Carlo G. Tocchetti, David A. Wink, Adrian J. Hobbs, Jon M. Fukuto

Research output: Contribution to journalReview article


Nitroxyl (HNO), the 1-electron reduced and protonated congener of nitric oxide (NO), has received recent attention as a potential pharmacological agent for the treatment of heart failure and as a preconditioning agent for the mitigation of ischemia-reperfusion injury. Interest in the pharmacology and biology of HNO has prompted examination, or in some instances reexamination, of many of its chemical properties. Such studies have provided insight into the chemical basis for the biological effects of HNO, although the biochemical mechanisms for many of these effects remain to be established. In this review, a brief description of the biologically relevant chemistry of HNO is given, followed by a more detailed discussion of the pharmacology and potential toxicology of HNO.

Original languageEnglish (US)
Pages (from-to)442-458
Number of pages17
JournalPharmacology and Therapeutics
Issue number2
StatePublished - Feb 1 2007



  • Angeli's salt
  • Calcitonin gene-related peptide
  • Heart failure
  • Inotropy
  • Ischemia-reperfusion
  • Myocardium
  • Nitric oxide
  • Nitroxyl
  • Platelets
  • Thiols
  • Thrombosis
  • Vasorelaxation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this